Tideglusib clinical trials
Also written NP031112 and NP-12.
How each study uses tideglusib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tideglusib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2016 | 2 |
| 2021 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 3
AMO Pharma Limited (3) · Noscira SA (3) · Holland Bloorview Kids Rehabilitation Hospital (1) · University of Zurich (1) · Hamilton Health Sciences Corporation (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test tideglusib, phase 3 first.
- Dec 2026Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic DystrophyPhase 2/3 · AMO Pharma Limited
- Feb 2027Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic CardiomyopathyPhase 2 · Hamilton Health Sciences Corporation
Studies
Open first, then newest update. How each study uses tideglusib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic CardiomyopathyRecruitingPhase 2Hamilton Health Sciences CorporationNCT06174220Written as Tideglusib
- Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic DystrophyRecruitingPhase 2/3AMO Pharma LimitedNCT05004129Written as Tideglusib
- Tideglusib for the Treatment of Amyotrophic Lateral SclerosisNot yet recruitingPhase 2University of ZurichNCT05105958Written as Tideglusib
- Efficacy and Safety of Tideglusib in Congenital Myotonic DystrophyCompletedPhase 2/3AMO Pharma LimitedNCT03692312Written as Tideglusib
- Study of Tideglusib in Adolescent and Adult Patients With Myotonic DystrophyCompletedPhase 2AMO Pharma LimitedNCT02858908Written as Tideglusib
- Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum DisordersCompletedPhase 2Holland Bloorview Kids Rehabilitation HospitalNCT02586935Written as Tideglusib
- Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease PatientsCompletedPhase 2Noscira SANCT01350362Written as tideglusib
- Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear PalsyCompletedNot applicableNoscira SANCT01049399Written as tideglusib
- Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s DiseaseCompletedPhase 1/2Noscira SANCT00948259Written as NP031112
Codes
What other systems call tideglusib · ClinicalTrials.gg INT005101
- MeSH (NLM) C520571tideglusibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) Q747Y6TT42TIDEGLUSIBConfirmed FDA, NLM, Wikidata
- Wikidata Q10382411tideglusibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97364TideglusibOne source FDA
- DrugBank DB12129One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C520571 | tideglusib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | Q747Y6TT42 | TIDEGLUSIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q10382411 | tideglusib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97364 | Tideglusib | One source FDA |
| DrugBank | DB12129 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.